These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 22739204)

  • 1. [Histone deacetylase inhibitors for the treatment of myelodysplastic syndrome].
    Zhi YQ; Guo SQ; Zhang YZ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Jun; 20(3):792-5. PubMed ID: 22739204
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lost in translation? Ten years of development of histone deacetylase inhibitors in acute myeloid leukemia and myelodysplastic syndromes.
    Stahl M; Gore SD; Vey N; Prebet T
    Expert Opin Investig Drugs; 2016; 25(3):307-17. PubMed ID: 26807602
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current status of epigenetic treatment in myelodysplastic syndromes.
    Kuendgen A; Lübbert M
    Ann Hematol; 2008 Aug; 87(8):601-11. PubMed ID: 18392623
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Myelodysplastic syndrome and histone deacetylase inhibitors: "to be or not to be acetylated"?
    Stintzing S; Kemmerling R; Kiesslich T; Alinger B; Ocker M; Neureiter D
    J Biomed Biotechnol; 2011; 2011():214143. PubMed ID: 21629744
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Deacetylase inhibitors for the treatment of myelodysplastic syndromes.
    Jabbour E; Garcia-Manero G
    Leuk Lymphoma; 2015 May; 56(5):1205-12. PubMed ID: 25058371
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epigenetic regulation in myelodysplastic syndromes: implications for therapy.
    Vigna E; Recchia AG; Madeo A; Gentile M; Bossio S; Mazzone C; Lucia E; Morabito L; Gigliotti V; Stefano LD; Caruso N; Servillo P; Franzese S; Fimognari F; Bisconte MG; Gentile C; Morabito F
    Expert Opin Investig Drugs; 2011 Apr; 20(4):465-93. PubMed ID: 21381982
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vorinostat in acute myeloid leukemia and myelodysplastic syndromes.
    Prebet T; Vey N
    Expert Opin Investig Drugs; 2011 Feb; 20(2):287-95. PubMed ID: 21192773
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Six (or more) drugs in search of a mechanism: DNA methyltransferase and histone deacetylase inhibitors in the treatment of myelodysplastic syndromes.
    Gore SD
    J Natl Compr Canc Netw; 2006 Jan; 4(1):83-90. PubMed ID: 16403407
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epigenetic therapy for myelodysplastic syndromes has entered center stage.
    Lübbert M
    Leuk Res; 2009 Dec; 33 Suppl 2():S27-8. PubMed ID: 20004795
    [No Abstract]   [Full Text] [Related]  

  • 10. The role of hypomethylating agents in myelodysplastic syndrome: changing the management paradigm.
    Merkel DG; Nagler A
    Expert Rev Hematol; 2013 Dec; 6(6):665-76. PubMed ID: 24191866
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epigenetic modulation and other options to improve outcome of stem cell transplantation in MDS.
    Kröger N
    Hematology Am Soc Hematol Educ Program; 2008; ():60-7. PubMed ID: 19074059
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epigenetics in focus: pathogenesis of myelodysplastic syndromes and the role of hypomethylating agents.
    Santini V; Melnick A; Maciejewski JP; Duprez E; Nervi C; Cocco L; Ford KG; Mufti G
    Crit Rev Oncol Hematol; 2013 Nov; 88(2):231-45. PubMed ID: 23838480
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro basis for treatment with hypomethylating agents and histone deacetylase inhibitors: can epigenetic changes be used to monitor treatment?
    Gore SD
    Leuk Res; 2009 Dec; 33 Suppl 2(Suppl 2):S2-6. PubMed ID: 20004793
    [TBL] [Abstract][Full Text] [Related]  

  • 14. More is better: combination therapies for myelodysplastic syndromes.
    Ornstein MC; Mukherjee S; Sekeres MA
    Best Pract Res Clin Haematol; 2015 Mar; 28(1):22-31. PubMed ID: 25659727
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rational combinations using HDAC inhibitors.
    Bots M; Johnstone RW
    Clin Cancer Res; 2009 Jun; 15(12):3970-7. PubMed ID: 19509171
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic epigenetics: an emerging clinical approach to hematologic malignancies.
    Clin Adv Hematol Oncol; 2005 Mar; 3(3 Suppl 1):1-10; quiz 11-2. PubMed ID: 21438190
    [No Abstract]   [Full Text] [Related]  

  • 17. Histone deacetylase inhibitors for the treatment of myelodysplastic syndrome and acute myeloid leukemia.
    Quintás-Cardama A; Santos FP; Garcia-Manero G
    Leukemia; 2011 Feb; 25(2):226-35. PubMed ID: 21116282
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Do histone deacytelase inhibitors and azacitidine combination hold potential as an effective treatment for high/very-high risk myelodysplastic syndromes?
    Badar T; Atallah E
    Expert Opin Investig Drugs; 2021 Jun; 30(6):665-673. PubMed ID: 33836635
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Molecular target therapy for myelodysplastic syndrome].
    Morita Y; Tanaka H; Matsumura I
    Nihon Rinsho; 2012 Nov; 70 Suppl 8():508-12. PubMed ID: 23513892
    [No Abstract]   [Full Text] [Related]  

  • 20. Emerging biological therapies for the treatment of myelodysplastic syndromes.
    Zeidan AM; Stahl M; Komrokji R
    Expert Opin Emerg Drugs; 2016 Sep; 21(3):283-300. PubMed ID: 27486848
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.